- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.
Essen Bakery owner Tova du Plessis recently took to social media to document her struggle and recent diagnosis of Narcolepsy Type 1. She has been struggling with the rare disease for 14 months, and according to her, that time has been “debilitating”, making it difficult to run the bakery and oversee the brand’s expansion to […]